母親の循環中のトリオドチロニンと,その後の妊娠前出血症のリスクとの関連
Jiang-Nan Wu1, Faustino R Pérez-López2,3, Ignacio Rodríguez4
1Obstetrics and Gynecology Hospital, Fudan University, 566 Fangxie Road, Shanghai, 200011, China. wjnhmm@126.com.
European journal of medical research
|September 4, 2025
まとめ
母親の甲状腺ホルモンのレベル,特にトライオードチロニン (TT3) は,妊娠前出血症のリスク増加と関連しています. TT3の上昇は,特に早期発症の場合には,妊娠前出血症のバイオマーカーとして機能する.
科学分野:
- 内分泌学
- 産婦人科
- 甲状腺 研究
背景:
- 妊娠前出血症は 妊婦と胎児の罹患率の重要な原因です
- 甲状腺ホルモンの役割,特にトライヨドチロニン (TT3) が妊娠前出血症の病原性にはっきりしない.
- これらの関連性を理解することは リスクの評価と管理に不可欠です
研究 の 目的:
- 妊婦のTT3濃度と妊娠前出血症の発症リスクとの関連を調査する.
- 早期発症の妊娠前出血症や甲状腺機能障害などの潜在的な変異因子や特定の臨床シナリオを調査する.
主な方法:
- 全般的な甲状腺検査による妊婦の病院ベースのコホート研究.
- 潜在的混乱要因を制御するために,指向アサイクルグラフ (DAG) を利用した.
- TT3濃度と妊娠前出血症リスクとの関連性を評価し,サブグループ分析と相互作用効果を評価した.
主要な成果:
- 妊婦のTT3濃度は妊娠前出血症のリスクと有意に関連していた (OR2. 32,95%CI2. 02-2.
- 早期発症の妊娠前出血症ではJ型関連が観察され,甲状腺刺激ホルモンが2.5μIU/ mL (OR 17. 22) を超えるとリスクが顕著であった.
- 18週以上の妊娠年齢は,TT3前出血症の関連性を変化させた (相互作用OR3. 22).
結論:
- 妊婦のTT3濃度の上昇は,妊娠前出血症のリスクが高くなります.
- TT3は妊娠前出血症の発生に作用し,重要な臨床バイオマーカーとなる可能性があります.
- この関連性は,特に早期発症の妊娠前出血症や,根本的な甲状腺機能不全の症例において重要である.
関連する概念動画
Pathophysiology of Diabetes
1.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Synthesis and Regulation of Thyroid Hormones
5.1K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
5.1K
Hormonal Regulation
33.7K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.7K
Regression Toward the Mean
6.5K
Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when...
6.5K
Diabetes Mellitus: Type 2 and Gestational
2.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.9K
Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K


